SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-072871
Filing Date
2024-03-21
Accepted
2024-03-20 17:32:00
Documents
20
Period of Report
2024-03-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d799248d8k.htm   iXBRL 8-K 35593
2 EX-1.1 d799248dex11.htm EX-1.1 222055
3 EX-4.1 d799248dex41.htm EX-4.1 63583
4 EX-5.1 d799248dex51.htm EX-5.1 7226
5 EX-10.1 d799248dex101.htm EX-10.1 89068
6 EX-99.1 d799248dex991.htm EX-99.1 11054
10 GRAPHIC g799248g0320005212421.jpg GRAPHIC 3645
11 GRAPHIC g799248g0320010859148.jpg GRAPHIC 2661
  Complete submission text file 0001193125-24-072871.txt   674136

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA fate-20240319.xsd EX-101.SCH 2877
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20240319_lab.xml EX-101.LAB 17235
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20240319_pre.xml EX-101.PRE 10830
24 EXTRACTED XBRL INSTANCE DOCUMENT d799248d8k_htm.xml XML 3541
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 24768707
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)